InspireMD Company Overview

Positive CGuard TM Clinical Experience CARENET Clinical Trial (2014) • 30 Patient Safety and Efficacy clinical trial . • . InspireMD Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%*) 50% fewer new ischemic lesions with lesion volume being 10x times smaller compared to historical non-mesh carotid artery stenting data All new ischemic lesions fully resolved at 30 days except one • 3.6% MACCE rate at 6 months (Comparative data 8.09%**) . Zero strokes or stroke related deaths at 12 months PARADIGM 101 Clinical Trial (2015, 2016, and 2018) • 101 patient trial evaluating CGuard EPS in unselected, consecutive carotid patients (all-comers) 99.1% device success • 0% MACCE (Death/stroke/MI) @ 48 hr • 0% MACCE @ 30 day • Zero strokes or stroke related deaths at 12 months "CGuard can safely be used on more than 90% of all- comer patients that have carotid artery stenosis." P. Musialek, MD . • No device-related adverse events and no procedure-related events at 24 months* Sustained stroke prevention at 24 months * Trials included in analysis: ARCHER pooled, ARMOUR, BEACH, CABERNET, CREATE, EMPIRE, EPIC, MAVERIC 1+2, MAVERIC International, PRIAMUS, SAPPHIRE, SECURITY, PROFI, ICSS ** Values extrapolated from event curves *** Musialek, ICCA 2018 *** 12 12

View entire presentation